DUPA(OtBu)-OH

Research use only, not for human use.

DUPA(OtBu)-OH is a DUPA precursor.

DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

DUPA(OtBu)-OH (DUPA precursor 17) is a 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA) reagent. The targeting ligand DUPA enhances the transport capability and selectivity of Paclitaxel (PTX) to tumor cells via prostate-specific membrane antigen (PSMA) mediated endocytosis. Besides, DUPA is conjugated with PTX via a disulfide bond, which facilitates the rapid and differential drug release in tumor cells.

DUPA-targeted Docetaxel (DTX) conjugate with longer spacer has no toxicity in major organs of treated mice.

——

Others

Other Targets

Others

——

——

1026987-94-9

488.57

C23H40N2O9

>98% (HPLC)

DMSO:125 mg/mL (255.85 mM; Need ultrasonic)

CC(C)(C)OC(=O)CC[C@@H](C(=O)OC(C)(C)C)NC(=O)N[C@@H](CCC(=O)O)C(=O)OC(C)(C)C

——

(-20℃)

With Ice Pack

≥ 2 years